Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84303 trials found · Page 15 of 4216
-
Universal 'Off-the-Shelf' cell therapy tested as potential reset for stubborn autoimmune diseases
Disease control Recruiting nowThis is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C. QT-219C is a universal allogeneic chimeric antigen receptor T-cell (CAR-T) product targeting both CD19 and BCMA. The study tar…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Tiny twin pumps aim to bridge the gap for patients waiting for new hearts
Disease control Not yet recruitingAdvanced heart failure is a life-threatening condition characterized by the inability of one or both ventricles to maintain adequate blood circulation. In such cases, medical treatments often prove ineffective, necessitating advanced treatment. Heart transplantation is the standa…
Phase: NA • Sponsor: Shenzhen Core Medical Technology CO.,LTD. • Aim: Disease control
Last updated Apr 21, 2026 19:43 UTC
-
New strategy aims to shrink liver tumors for surgery
Disease control Not yet recruitingThis study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the…
Phase: NA • Sponsor: Hong Wu • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Smart blood test guides fight against tough lymphoma
Disease control Not yet recruitingEvaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
New drug combo aims to boost power of CAR-T cancer therapy
Disease control Not yet recruitingThe purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Weekly shot aims to tackle weight and diabetes in major new trial
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of RO7795068, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
New hope for advanced stomach cancer patients in major drug delivery trial
Disease control Not yet recruitingA Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 13, 2026 20:08 UTC
-
New hope for tough lung cancers: experimental combo challenges standard chemo
Disease control Not yet recruitingThis is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced or metastatic non-squamous non-small cell lung canc…
Phase: PHASE3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Precision brain surgery trial aims to save lives and reduce disability
Disease control Not yet recruitingIntroduction: Minimally invasive puncture surgery with thrombolysis is effective for hypertensive intracerebral hemorrhage, but its effect on neurological recovery remains uncertain. The use of neuronavigation-assisted stereotactic technology can significantly improve the precisi…
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
New drug combo could spare bladder cancer patients from Life-Altering surgery
Disease control Not yet recruitingPeople with a type of bladder cancer called muscle-invasive bladder cancer have cancer that has spread into the muscle wall of the bladder. The standard treatment is to have chemotherapy, followed by surgery to completely remove the bladder. This has a significant impact on peopl…
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 06, 2026 14:19 UTC
-
Major trial launches hopeful new attack on deadly pancreatic cancer
Disease control Not yet recruitingThis is a phase III, multi-center study to evaluate the efficacy and safety of chiauranib plus plus toripalimab, albumin-paclitaxel and gemcitabine as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma. The study includes two period: Run-in period and…
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
New drug combo offers hope for patients out of chemo options
Disease control Recruiting nowThis study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other important questions include: Is their quality of life …
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New drug trial offers hope for shrinking painful NF1 tumors
Disease control Recruiting nowThis study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Head-to-Head showdown: new drug combo challenges standard for tough lung cancer
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Part…
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Apr 06, 2026 14:15 UTC
-
New hope for advanced cervical cancer: major trial tests powerful drug combo
Disease control Not yet recruitingThis study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.
Phase: PHASE3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New hope to stop deadly leukemia relapse after transplant
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell transplant (HSCT) of patients with Philadelphia chromosome…
Phase: PHASE2 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New hope for women with Tough-to-Treat cervical cancer
Disease control Recruiting nowThe main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
Brain chip trial aims to rewire Stroke-Damaged minds for movement
Disease control Not yet recruitingThe clinical investigation will take place in three phases: * A pre-selection/selection phase to ensure that the patient (lesion, symptoms, ability of our tools to detect your movement intentions, etc.) is suitable for a six-month intensive rehabilitation program using Brain-Mac…
Phase: NA • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo trial aims to control aggressive blood cancer
Disease control Recruiting nowThis phase II trial tests the effect of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) with or without rituximab plus ponatinib in treating patients newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leu…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New hope for kids with Tough-to-Treat leukemia
Disease control Not yet recruitingMulti-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion. Part 1 dose escalation will enroll participants aged ≥1 yea…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC